Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders

被引:42
|
作者
Xu, Yang [1 ]
Alfaro-Magallanes, Victor M. [1 ,2 ]
Babitt, Jodie L. [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Program Membrane Biol, Div Nephrol, Boston, MA 02115 USA
[2] Univ Politecn Madrid UPM, Fac Phys Act & Sport Sci, Dept Hlth & Human Performance, LFE Res Grp, Madrid, Spain
基金
美国国家卫生研究院;
关键词
iron; anaemia; hepcidin; thalassaemia; hereditary haemochromatosis; bone morphogenetic protein; ANTIMICROBIAL PEPTIDE HEPCIDIN; PROTEASE MATRIPTASE-2 TMPRSS6; CHRONIC KIDNEY-DISEASE; MOUSE MODEL; BETA-THALASSEMIA; DEFICIENCY ANEMIA; AMELIORATES HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR-2; TARGETED DISRUPTION; DARBEPOETIN ALPHA;
D O I
10.1111/bjh.17252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The discovery of hepcidin has provided a solid foundation for understanding the mechanisms of systemic iron homeostasis and the aetiologies of iron disorders. Hepcidin assures the balance of circulating and stored iron levels for multiple physiological processes including oxygen transport and erythropoiesis, while limiting the toxicity of excess iron. The liver is the major site where regulatory signals from iron, erythropoietic drive and inflammation are integrated to control hepcidin production. Pathologically, hepcidin dysregulation by genetic inactivation, ineffective erythropoiesis, or inflammation leads to diseases of iron deficiency or overload such as iron-refractory iron-deficiency anaemia, anaemia of inflammation, iron-loading anaemias and hereditary haemochromatosis. In the present review, we discuss recent insights into the molecular mechanisms governing hepcidin regulation, how these pathways are disrupted in iron disorders, and how this knowledge is being used to develop novel diagnostic and therapeutic strategies.
引用
收藏
页码:882 / 893
页数:12
相关论文
共 50 条
  • [1] POSTPRANDIAL HYPOTENSION - PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS IN DIFFERENT DISORDERS
    MATHIAS, CJ
    DIBONA, G
    BRODY, M
    MARK, A
    SOMERS, VK
    SCHMID, P
    CHAPLEAU, M
    HYPERTENSION, 1991, 18 (05) : 694 - 704
  • [2] Mechanisms of Disease: the role of hepcidin in iron homeostasis—implications for hemochromatosis and other disorders
    Antonello Pietrangelo
    Christian Trautwein
    Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 : 39 - 45
  • [3] Mechanisms of disease: the role of hepcidin in iron homeostasis - Implications for hemochromatosis and other disorders
    Pictrangelo, Antonello
    Trautwein, Christian
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (01): : 39 - 45
  • [4] Hepcidin in human iron disorders: Therapeutic implications
    Pietrangelo, Antonello
    JOURNAL OF HEPATOLOGY, 2011, 54 (01) : 173 - 181
  • [5] Hepcidin in Human Iron Disorders: Diagnostic Implications
    Kroot, Joyce J. C.
    Tjalsma, Harold
    Fleming, Robert E.
    Swinkels, Dorine W.
    CLINICAL CHEMISTRY, 2011, 57 (12) : 1650 - 1669
  • [6] Hepcidin in human iron disorders: diagnostic implications
    Kroot, Joyce Jc
    Tjalsma, Harold
    Fleming, Robert E.
    Swinkels, Dorine W.
    BIOCHIMICA CLINICA, 2013, 37 (02) : 108 - 127
  • [7] Clinical Implications of New Insights into Hepcidin-Mediated Regulation of Iron Absorption and Metabolism
    Prentice, Andrew M.
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 40 - 48
  • [8] Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD
    Babitt, Jodie L.
    Lin, Herbert Y.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : 726 - 741
  • [9] Neurosteroids in eating disorders: Pathophysiological and clinical implications
    Monteleone, P
    Castaldo, E
    Longobardi, S
    Pannuto, M
    Maj, M
    EUROPEAN PSYCHIATRY, 2004, 19 : 91S - 91S
  • [10] Hepcidin and iron disorders: new biology and clinical approaches
    Arezes, J.
    Nemeth, E.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 : 92 - 98